Cigna’s price has retreated to the $280‑$285 range but remains above its 200‑day moving average, with RSI edging into oversold territory and a bullish MACD crossover. The pullback aligns with strong earnings, robust cost‑synergy forecasts and a healthier valuation after the CVS settlement.

Investors view the recent dip as a buying opportunity, buoyed by sector‑wide optimism and the FTC‑CVS settlement’s perceived benefit to Cigna’s pharmacy‑network margins. Broad market sentiment stays supportive of health‑care names.

While valuation pressure and regulatory scrutiny pose moderate risks, Cigna’s long‑term growth drivers—Medicare Advantage enrollment and expanding PBM services—remain intact. The long‑run outlook stays positive despite short‑term price weakness.

Technical data shows the 5‑day SMA breaking above the 20‑day SMA, a bullish MACD histogram turn, and elevated volume on the recent gap‑down, all pointing to upside momentum. Signal strength suggests a higher‑probability move toward $300.